South Africa has one of the highest burdens of TB and (Drug Resistant) DR-TB in the world, with around 20,000 people diagnosed with DR-TB in 2015. In Khayelitsha, Western Cape, which has some of the country’s highest rates of DR-TB, MSF runs a strengthened regimen programme that incorporates new drugs into treatment regimens for DR-TB patients including Delamanid and Bedaquiline. Photograph by Sydelle WIllow Smith
Issue brief |

Drug-resistant tuberculosis treatment & access to delamanid in South Africa

TUBERCULOSIS
South Africa
TB_Briefing_DelamanidInSouthAfrica_ENG_2016.pdf
Photograph by Sydelle WIllow Smith

South Africa has one of the highest burdens of tuberculosis (TB) and drug-resistant tuberculosis (DR-TB) in the world. In 2015, almost 300,000 people were diagnosed with TB in South Africa, including 20,000 with some form of DR-TB. This briefing document examines the current DR-TB treatment, the role of delamanid in DR-TB treatment, and barriers to accessing delamanid in South Africa.